

### Investment Objective

To achieve consistent capital appreciation over the medium to long term by investing mainly in companies that have been systematically filtered through a series of proven pre-determined financial criteria.

### Investor Profile

The fund is suitable for investors who are willing to accept risk for returns presented by the stock market and have a medium to long term investment horizon.

### Fund Manager

UOB Asset Management (Malaysia)

### Fund Details


Unit NAV	RM3.3817
Fund Size	RM92.5 million
Inception Date	1 April 2005
Management Fee	1.50% per annum

### Top 10 Holdings

Frontken	8.6%
Dufu Technology	8.1%
Supermax	7.3%
Top Glove	6.1%
Pentamaster	5.8%
Tenaga Nasional	4.9%
Mega First Corp	3.5%
Unisem	2.8%
Duopharma Biotech	2.7%
Power Root	2.7%

Data as at 31 August 2020

### Cumulative Performance Since Inception as at 31 August 2020




### Performance Table as at 31 August 2020

	1 month	3 months	6 months	YTD	1 year	3 years	5 years	Since inception
<b>Fund</b>	6.1%	32.2%	37.8%	31.0%	57.4%	83.9%	124.5%	611.9%
<b>Benchmark</b>	-2.9%	5.9%	5.8%	-2.1%	-2.3%	-12.1%	1.0%	89.0%

- Benchmark: FTSE Bursa Malaysia Emas Index
- Source: Bloomberg & Gibraltar BSN Life Bhd

Past performance is not indicative of future performance and the performance of the fund is not guaranteed.

### Portfolio Composition as at 31 August 2020



Source: UOBAM



**Manager's Comment**

For August 2020, the Fund's NAV/unit increased by 6.1%, outperformed FBM EMAS which decreased by 2.9% due to stock selection especially the Fund's position in technology and export related stocks. These stocks rose on better than expected Q2 earnings and outlook despite the disruptions caused by the Covid-19 pandemic.

Markets rose for the second consecutive month driven by recovery optimism as businesses restart, positive newsflow on vaccine development and a slowdown in global infection growth. Oil prices recovered due to anticipated demand as major countries come out of lockdown coupled with global supply cuts.

The FBM KLCI Index gained 4.7% to close at 1,473 points led by gains in the healthcare sector. The Bursa Malaysia Healthcare Index gained 55.4% for the month driven by the stronger-than-expected pricing power of the glove makers, which supply up to 63% of global demand. Meanwhile, FBM Small Cap Index surged 9% to close at 12,062 points.

Brent oil gained 40% to close at US\$35/bbl while CPO gained 9.8%. The Ringgit weakened against the US Dollar by 1.2% to 4.35.

Looking ahead, we have a neutral view on equities in the near term in view of the increasing uncertainties and the strong recovery in equities since bottoming in March. Hence, we plan to lock in some gains on outperforming stocks. Additionally, we would focus on stock selection to generate outperformance. Our preferred sectors are IT (semiconductor) and healthcare.

**For Internal Use Only**

**Disclaimer**

This report is for information only and is purely a product summary. Please refer to the product fact sheet available at [www.gibraltarbsn.com](http://www.gibraltarbsn.com) for further details. This report shall not be reproduced, copied, circulated or forwarded either in part or otherwise to any persons howsoever without the prior written consent of Gibraltar BSN Life Berhad.

The opinions and information contained herein are based on the latest available data which is believed to be reliable. It is not to be construed as an offer, invitation or solicitation to buy or sell any securities or financial instruments covered by this report. Gibraltar BSN Life Berhad does not warrant the accuracy of anything stated herein in any manner whatsoever and no reliance upon such statement by anyone shall give rise to any claim whatsoever against Gibraltar BSN Life Berhad and/or its associated persons. Gibraltar BSN Life Berhad and/or its associated persons may from time to time have an interest in the securities or financial instruments mentioned by this report. Past Performance of the Funds mentioned in the Report is not an indication of its future performance. Investors/policy holders should rely on their own evaluation to assess the merits and risks of the investment. In considering to invest in an investment-linked fund, investors/policy holders who are in doubt on the action to be taken should consult a professional adviser. Investors/Policy holders have to take note that investments can fluctuate in value and values may fall as well as rise and an investor/policy holder may not get back the amount invested.